Compare DexCom, Inc. (DXCM) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs ArcelorMittal SA — how do they compare? DexCom, Inc. trades at $83.36 (market cap $31.86B), while ArcelorMittal SA trades at $64.3 (market cap $45.70B). The key difference: ArcelorMittal SA is the larger of the two by market cap, and ArcelorMittal SA pays a 0.98% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and ArcelorMittal SA for 36 Days on average.
| DXCM | MT | |
|---|---|---|
Market Cap | $31.86B | $45.70B |
Volume | 3,607,070 | 1,964,621 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $78.74 |
52-Week Low | $54.84 | $36.91 |
Typical Hold Time | 62 Days | 36 Days |
Enterprise Value | $31.32B | $55.27B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
ArcelorMittal (MT) trades at $64.18, up 2.98% with mixed technical signals showing bearish moving averages but bullish oscillators. The company maintains solid fundamentals with a P/E of 25.76 and P/S of 0.75, though recent Q2 2026 earnings missed expectations. Revenue has declined from $79.8B in 2022 to $61.4B in 2025, while net income improved to $3.2B. Recent news highlights operational challenges in Ukraine with a $1B impairment charge, but strategic partnerships and European demand improvements provide offsetting positives.
The outlook remains cautiously optimistic with analyst consensus price target of $74.33 representing 16% upside potential. Key opportunities include expanding steel capacity and regionalization benefits, while risks involve ongoing Ukraine operations disruption, China demand weakness, and elevated capital expenditures. Institutional sentiment leans bullish with 52% buy ratings, though technical resistance near $62-63 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
